Jacklyn Eyre
Medical · Spring, TXNPI 1336487198
Payments from drug & device makers
Across 481 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$1K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- AbbVie$556
- Bayer$471
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,236100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 123 | $1,707 |
| Amgen | 72 | $1,244 |
| Lilly USA, LLC | 67 | $1,233 |
| AstraZeneca | 38 | $1,200 |
| AbbVie | 25 | $556 |
| Bayer | 24 | $471 |
| Pfizer | 13 | $312 |
| Esperion Therapeutics, Inc. | 11 | $293 |
| GSK | 11 | $288 |
| Boehringer Ingelheim | 15 | $278 |
| Sanofi-aventis U.S. LLC | 7 | $196 |
| Regeneron Healthcare Solutions, Inc. | 3 | $187 |
| Kowa Pharmaceuticals America, Inc. | 17 | $146 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $134 |
| Sumitomo Pharma America, Inc. | 6 | $107 |
| Corcept Therapeutics | 2 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $80 |
| Dexcom, Inc. | 4 | $78 |
| Amarin Pharma, Inc. | 4 | $74 |
| Cranial Technologies, Inc | 5 | $72 |
| Biohaven Pharmaceuticals, Inc. | 4 | $70 |
| Merck | 4 | $58 |
| Abbott | 3 | $50 |
| Seqirus USA Inc | 2 | $48 |
| Boston Scientific | 1 | $43 |
| Exact Sciences | 2 | $31 |
| Medicure Pharma Inc. | 1 | $28 |
| Lucid Diagnostics Inc. | 1 | $26 |
| Biogen | 1 | $25 |
| Nevro Corp. | 1 | $24 |
| Edwards Lifesciences | 1 | $22 |
| Novartis | 1 | $20 |
| Johnson & Johnson | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,238 in reported general payments places this provider in the 90th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $45,033 |
| EliquisApixaban | 33 | $40,187 |
| TrulicityDulaglutide | 25 | $37,157 |
| FarxigaDapagliflozin Propanediol | 32 | $31,064 |
| JardianceEmpagliflozin | 22 | $21,366 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $17,381 |
| MounjaroTirzepatide | 11 | $13,713 |
| VascepaIcosapent Ethyl | 12 | $7,575 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,409 |
| SynthroidLevothyroxine Sodium | 40 | $3,384 |
| Rosuvastatin Calcium | 178 | $3,203 |
| Levothyroxine Sodium | 237 | $2,327 |
| Atorvastatin Calcium | 233 | $2,108 |
| Ezetimibe | 74 | $1,669 |
| Valsartan | 21 | $1,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,233 | $50,87036 claims |
| Novo NordiskOzempic | $1,707 | $45,03332 claims |
| PfizerEliquis | $312 | $40,18733 claims |
| AstraZenecaFarxiga | $1,200 | $31,06432 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $288 | $21,78929 claims |
| Boehringer IngelheimJardiance | $278 | $21,36622 claims |
| AbbVieSynthroid | $556 | $3,38440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,490 medical providers in Texas.
Other medical in Spring
- Kendra CookSpring$20K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.